ArticleJHEP reports : innovation in hepatology2022

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.

Christoph Schramm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.